Company |
Drug |
Indication |
Abbvie Inc. (North Chicago) |
Imbruvica |
Relapsed/refractory marginal zone lymphoma |
Adapt Pharma Inc. (Dublin) |
Narcan nasal spray 2-mg |
Emergency treatment of known or suspected opioid overdose |
Allergan plc (Dublin) |
Rhofade 1% cream |
Persistent facial erythema associated with rosacea |
Allergan plc (Dublin) |
Avycaz |
Complicated urinary tract infections (cUTI) |
Astrazeneca plc (London) |
Symbicort inhalation aerosol 80/4.5 mcg |
Asthma |
Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Co. (Indianapolis) |
Synjardy, Synjardy XR and Glyxambi |
Type 2 diabetes and cardiovascular disease |
Egalet Corp. (Wayne, Pa.) |
Arymo ER extended-release (ER) tablets C-II |
Pain |
Genentech (unit of Roche Holding AG; Basel, Switzerland) |
Lucentis, injected, 0.5 mg |
Myopic choroidal neovascularization |
Ironwood Pharmaceuticals Inc. (Cambridge, Mass.) and Allergan plc (Dublin) |
Linzess |
Chronic idiopathic constipation (CIC) |
Roxane Laboratories Inc. (wholly owned U.S. subsidiary of Hikma Pharmaceuticals plc; London) |
Sodium oxybate oral solution, 500 mg/mL |
Cataplexy, or sudden loss of muscle strength, and excessive daytime sleepiness in patients with narcolepsy |
Synergy Pharmaceuticals Inc. (New York) |
Trulance |
Chronic idiopathic constipation |
Teva Pharmaceutical Industries Ltd. (Jerusalem) |
Vantrela ER |
Severe pain |